Familial Hypercholesterolaemia (FH) Arrays Rapid and reliable genetic assessment of patients with suspected FH

Familial Hypercholesterolaemia (FH) Arrays I & II Rapid, simultaneous detection of 40 mutations within the LDLR, ApoB and PCSK9 genes Introduction Familial Hypercholesterolemia (FH) is a genetic disorder of lipoprotein metabolism. It is a common autosomal dominant, or inherited, disease which affects the plasma clearance of LDL-cholesterol (LDL-C), resulting in premature onset of cardiovascular disease (CVD) and a higher mortality risk.1-3 Common genetic defects in FH are attributed to mutations in three genes encoding proteins involved in the uptake of LDL-C from the plasma: the low density...

Analyte Name Analyte Name FH Arrays I & II protocol Extraction Genomic DNA extracted from blood Amplicon hybridisation/ conjugation to biochip array results processing by Evidence Investigator analyser Benefits of the Randox Familial Hypercholesterolaemia (FH) Arrays I & II Product features • Rapid turnaround time of ~3 hours from extracted genomic DNA to result • Samples can be assessed in small batches (as few as 3 samples) with only 20ng of genomic DNA required per array Benefits to the laboratory • Developed with leading experts to test for 40 specific FH-causing mutations with ~78% coverage,...

PRECISE DIAGNOSTICS FOR TARGETED THERAPY Understanding drivers of disease is vital in delivering effective patient care. Through the unravelling of the genetic code, healthcare practitioners are able to predict and prevent disease and prescribe appropriate targeted treatments to specific subgroups, for optimal patient outcomes. Randox Molecular offers a range of assay formats including SNP genotyping, gene expression, pathogen detection and mutation detection across infectious diseases, cardiovascular disease and oncology. Utilising innovative Biochip Array Technology (BAT) for multi-analyte...